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ABSTRACT
RNA interference (RNAi) is a modality in which small
double-stranded RNA molecules (siRNAs) designed
to lead to the degradation of specific mRNAs are
introduced into cells or organisms. siRNA libraries
have been developed in which siRNAs targeting vir-
tually every gene inthe human genome are designed,
synthesized and are presented for introduction
into cells by transfection in a microtiter plate array.
These siRNAs can then be transfected into cells
using high-throughput screening (HTS) methodol-
ogies. The goal of RNAi HTS is to identify a set of
siRNAs that inhibit or activate defined cellular phe-
notypes. The commonly used analysis methods
including median±kMAD have issues about error
rates in multiple hypothesis testing and plate-wise
versus experiment-wise analysis. We propose a
methodology based on a Bayesian framework to
address these issues. Our approach allows for shar-
ing of information across plates in a plate-wise anal-
ysis, which obviates the need for choosing either
a plate-wise or experimental-wise analysis. The
proposed approach incorporates information from
reliable controls to achieve a higher power and a
balance between the contribution from the samples
and control wells. Our approach provides false
discovery rate (FDR) control to address multiple test-
ing issues and it is robust to outliers.
INTRODUCTION
RNA interference (RNAi) is a naturally occurring path-
way for the regulation of gene expression in which small
double-stranded RNAs (siRNAs) lead to the destruction of
mRNAswithcomplementarynucleosidesequences(1).This
pathway can be co-opted by experimentally introducing
synthetic 19–21-mer double stranded RNAs designed to
target speciﬁc mRNAs, thus knocking down the expression
ofthe proteinofinterest(2).RNAioﬀersaneﬀectivewayof
silencingageneandhasbeenseenasthethirdclassofdrugs,
after small molecules and proteins (3). The importance of
RNAi was further recognized when the Nobel Prize in
Medicine and Physiology was awarded to Drs Fire and
Mello in 2006 for their research in this ﬁeld. RNAi can be
utilizedonagenome-wide scale viahigh-throughputscreen-
ing (HTS) technology that allows thousands of siRNAs to
be tested in an unbiased manner to identify previously
unknown genes involved in a biological pathway. The
goal of RNAi HTS is to identify a set of siRNAs that inhi-
bitsoractivatesthecellularphenotypebeingevaluated.This
process is called hit selection. One of the most fundamental
challenges in HTS is to glean biological signiﬁcance from
mounds of data, which relies on thedevelopment andadop-
tion of appropriate statistical designs and analytic methods
for quality control and hit selection (4).
For hit selection, there are two major types of
approaches: one is the use of analytic metrics to assess
and rank the size of siRNA eﬀects and the other is the
use of hypothesis testing to control false positive and
false negative rates (5). In the ﬁrst approach, fold change,
mean diﬀerence, percent activity, percent viability, percent
inhibition and strictly standardized mean diﬀerence
(SSMD) have already been proposed and explored in the
literature (5–10). In the second approach, the most com-
monly used methods are the use of z-score or t-test for
testing the null hypothesis that no diﬀerence exists between
the means, i.e. mean±kSD or median±kMAD (median
absolute deviation) (11–17). These methods usually control
the false positive and false negative rates based on
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tested in an HTS assay, the false positive rate will be
inﬂated. Hence, one issue in these methods is the adjust-
ment of error rates in multiple hypothesis testing.
Another issue arising from these classical approaches
is whether to perform plate-wise or experiment-wise
analysis. The plate-wise analysis can adjust for diﬀerent
systematic errors within each plate. Previously, we demon-
strated that a plate-wise analysis has a higher probability
of detecting true, modestly eﬀective, hits than an
experiment-wise analysis when there are not cluster(s)
of true hits in any of the plates (17). However, plate-
wise analysis may produce misleading results if a cluster
of active siRNAs is located within a single plate. An
experiment-wise analysis is not aﬀected by the distribu-
tion of active siRNAs between plates; however, it cannot
adjust for systematic errors within each plate. Current
strategies require a decision on whether to use plate-
wise or experiment-wise analysis. Finally, all the above
methods of hit selection utilize information from only a
negative reference. It remains unresolved whether a nega-
tive control or the majority of sample wells should be
used as the negative reference to capture information on
the variability (18).
In this article, we propose a methodology based on
a Bayesian framework for hit selection to address the
issues encountered in the classical approaches described
above. Newton et al. (19) developed a Bayesian method
to control false discovery rate (FDR) for analyzing micro-
array data. Like Newton et al.’s method, our proposed
Bayesian method controls FDR via a direct posterior
probability approach. In addition, to adapt the Bayesian
FDR methods to solve issues of hit selection in genome-
scale RNAi screens, our method has the following unique
features. First, the proposed method incorporates infor-
mation from reliable controls; thus it maintains a balance
between the contributions from the sample and control
wells. For screens employing eﬀective positive and nega-
tive controls, an approach that utilizes this information
will be more powerful in hit selection. Second, the pro-
posed method implements robust statistical processes;
thus it is robust to outliers. Third, the priors of the pro-
posed method incorporate experiment-wise information
whereas the likelihoods are constructed in a plate-wise
base. Hence, this approach allows for sharing of infor-
mation across plates in a plate-wise analysis and thus,
eliminates the need to decide between a plate-wise or
experiment-wise analysis. We illustrate the performance
of our approach via both the case studies and simulations.
METHODS
An RNAi HTS experiment is usually conducted in
96-well, 384-well or 1536-well plates in which the cells in
a well are treated with a unique siRNA or a control.
A typical RNAi HTS project starts with a primary
screen of about 20000 to 50000 siRNAs most of which
have no replicate. The eﬀective siRNAs identiﬁed (called
‘hits’) in the primary screen are further investigated using
one or more conﬁrmatory screens in which each siRNA
has replicates. Currently, a typical primary screen may
have 50–200 384-well plates and a typical conﬁrmatory
screen may have 3–20 384-well plates. The measured
response is usually the intensity emitted by labeled parti-
cles such as ﬂuorescent dyes. For simplicity, in this article,
the term ‘intensity of an siRNA’ is used to refer to
‘the measured intensity of a phenotype corresponding
to the treatment of an siRNA’, which may be light inten-
sity, the intensity emitted by a dye or the ratio of intensity
emitted by two dyes depending on individual experiments.
Considering mathematical and computational conve-
nience for modeling the observations with normal distri-
bution, we typically log transform the raw intensity for
statistical analysis. All experiments include a positive con-
trol with speciﬁc knockdown eﬀects (usually occupying
4–16 wells) and a negative control with nonspeciﬁc knock-
down eﬀects (usually occupying 4–20 wells) in each plate.
Likelihood
Let X1,X2,...,XK be the log-transformed intensities of
sample siRNAs in a plate. Since each sample well consists
of unique siRNAs targeting diﬀerent genes, we assume
that each well has its own distribution. Assume that the
likelihood function is given by
Xij i   Nð i, 2Þ, 1
where  i is the unknown mean for sample siRNA i. For
the i-th siRNA, our hypotheses of interest are: H0: siRNA
i2{no eﬀect}, H1: siRNA i2{activation eﬀect} and H2:
siRNA i2{inhibition eﬀect}. Here, we construct two
Bayesian models using hypothesis testing to identify hits.
Prior distributions
Let the prior distribution for  i be  ( i). For simplicity,
we ﬁrst construct the prior for  i of sample siRNA i as
follows,
 i   Nð 0, 2Þ, 2
where  0 and  
2 are the center and variance of a negative
reference, i.e. an siRNA with no speciﬁc eﬀects.  0 is pre-
estimated using the mean of sample siRNA wells exclud-
ing outliers in a plate. This model (i.e. Model 1) is based
on the assumption that most of the sample siRNAs do not
have an activation/inhibition eﬀect. We could also use a
uniform prior if no prior information is available for  i.
However, this will be equivalent to the classical z-score
method or mean±kSD approach.  
2 in Model 1 is
assumed to be known and is obtained in the same way as
in our second model (i.e. Model 2) that is described below.
In cases where both eﬀective positive (activation and
inhibition) and negative controls are available and reli-
able, we propose using a prior that incorporates the infor-
mation from these controls for selecting activating or
inhibiting siRNAs, which leads to Model 2. Let the
prior be a mixture distribution
 i   p0 0 þ p1 1 þ p2 2, 3
where p0 is the prior proportion of nonhits, p1 is the prior
proportion of activation hits, p2 is the prior proportion of
inhibition hits and p0+p1+p2=1. The densities  0,  1
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esis. We assume that  0   Nð 0, 2Þ,  i   Nð 1, 2Þ and
 2   Nð 2, 2Þ. Other choices of  1’s are possible but our
case study suggests it is reasonable to model them as
normal distributions for simplicity. The parameters  0,
 1,  2,  
2, s
2, p0, p1, p2, in the model are obtained using
the methods provided in the following two paragraphs.
In a typical RNA HTS experiment, the negative control
wells are from an siRNA with unspeciﬁc eﬀects, e.g. lucif-
erase in our case study for HIV. The observed inten-
sities from the negative control wells in a plate can be
assumed to be independent and identically distributed as
Xij N   Nð N, 2Þ where  N is the mean of the negative
control. In many cases, the variability of the negative con-
trols can be assumed to be the same across plates within
each experiment. Therefore, we can pool the variability
estimates across the plates to allow information sharing.
This is also motivated by the fact that the number of
negative controls in each plate is usually small; thus if
we pool the information across the plates we can obtain
a better estimate. To reduce the impact of outliers, we
calculate the deviation of each well for a negative control
from the median of the negative control in each plate and
exclude outliers identiﬁed experiment wise using boxplot
parameters. That is, let Yij be the intensity (in log scale)
of the i-th negative control well and ~ Y j be the median of
intensities of negative control wells in plate j.
Let dij ¼ Yij   ~ Y j and apply a boxplot rule to dij experi-
ment wise to identify outliers for the negative control.
Apply ^  2 ¼ð
P
i
P
j ðYij     Y jÞ
2Þ=ð
P
j nj   AÞ to estimate s
2
of the negative control, where   Y j and nj are, respectively,
the mean and number of negative control wells after
excluding outliers in plate j and A is the total number
of plates. Similar reasoning can be extended to other
types of controls. The ﬁnal estimated s
2 can be obtained
by pooling ^  2’s from diﬀerent controls.
The unconditional variance of Xi is VarðXiÞ¼
E½VarðXij iÞ  þ Var½EðXij iÞ  ¼ E½ 2 þVar½ i ¼ 2þ
 2 P
p2
m where m=0,1,2. For Model 1, p0=1 and
p1=p2=0; for Model 2, pm’s can be estimated using
the EM algorithm similar to Newton et al. (19). A natural
estimate for Var(X) is the sample variance of the
intensities of sample siRNAs X1,X2,...,XK in a plate.
Given V^ arðXÞ and ^  2, an estimate for  
2 is max
fðV^ arðXÞ ^  2Þ=
P
p2
m,0g to avoid a negative variance esti-
mate.  0,  1, and  2 are estimated plate wise from the mean
of sample wells, activation control wells and inhibition
control wells, respectively, after excluding the correspond-
ing outliers in a plate. Note, outliers are excluded only
in the process of estimating the parameters  0,  1,  2, s
2
and  
2, but are included for further analysis such as
calculating their posteriors.
Posterior distributions
For our Model 1, using the likelihood given in
Equation (1) and prior distribution Equation (2), the pos-
terior distribution of  i is given by
 ijXi   N
 2 0 þ  2Xi
 2 þ  2 ,
 2 2
 2 þ  2
  
4
Our quantity of interest is  i in this model. From posterior
distribution Equation (4), the Bayesian framework here
allows for the inference on each sample siRNA incorpor-
ating both its own intensity Xi and the center of the nega-
tive reference  0, respectively, weighted by the variability
of the sample siRNAs and of the negative control.
For our Model 2, using the likelihood function
Equation (1) and prior distribution Equation (3), the pos-
terior distribution of  i is given by
fð ijXiÞ¼
fðXij iÞ ð iÞ Ð
fðXij iÞ ð iÞd i
¼ ~ p0~ f0 þ ~ p1~ f1 þ ~ p2~ f2 5
where
~ fm   N
 2 m þ  2Xi
 2 þ  2 ,
 2 2
 2 þ  2
  
and m=0,1,2
~ pm ¼
pm  ðXi    mÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
 2 þ  2 p   
P 2
k¼0
pk  ðXi    kÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
 2 þ  2 p   
~ pm’s are estimated using the EM algorithm similar to
Newton et al. (19), and   is the density function of stan-
dard normal distribution. From posterior distribution
Equation (5), the Bayesian framework here allows for
the inference on each sample siRNA incorporating both
its own intensity Xi and the mixture center of the controls P2
k¼0 ~ pk k, respectively, weighted by the variability of the
sample siRNAs distribution and of the negative reference.
Bayesian hypothesis testing
We are interested in the hypotheses H0: siRNA i2{no
eﬀect}, H1: siRNA i2{activation eﬀect} and H2: siRNA
i2{inhibition eﬀect}. An HTS experiment typically con-
sists of approximately 30000 siRNAs of interest. In other
words, we are conducting  30000 hypothesis tests simul-
taneously. Given the large number of hypothesis tests, an
eﬀective way of controlling the error rate is by using the
notion of FDR (19–21). We use the direct posterior prob-
ability approach to control FDR (19). One key in this
approach is the calculation of the probability that an
siRNA falls under each hypothesis given the data,
namely P(Hm|Xi).
Suppose large (small) values of  i relative to  0 are in
favor of the presence of activation (inhibition) eﬀect.
Under the prior in Model 1, for the i-th sample siRNA,
a decision rule based on priors can be set to be: siRNA
i2H0 (i.e. no eﬀect) if j i    0j a; siRNA i2H1
(i.e. activation eﬀect) if  i    0>a and siRNA i2H2
(i.e. inhibition eﬀect) if  i   0< a, where a is the 0.95
quartile of the prior distribution of  i, i.e. N ( 0,  
2).
Using these priors and the posterior distribution in for-
mula (4), we can obtain the posterior probabilities of
P(H0|Xi), P(H1|Xi) and P(H2|Xi) (i.e. P(| i  0| a|Xi),
P( i  0>a|Xi), and P( i  0  a|Xi), respectively)
under Model 1. Under Model 2, the posterior probabilities
of P(H0|Xi), P(H1|Xi), and P(H2|Xi) are, respectively,
~ p0, ~ p1 and ~ p2 in the posterior distribution in formula (5).
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only can be calculated as follows: suppose our goal is to
identify a list of J siRNAs for which H1 is true. Let
 i ¼ 1   PðH1jXiÞ: 6
We rank the siRNAs according to increasing values of
 i and declare the ﬁrst J siRNAs with values of  i less
than some bound k to be placed in the list. Because  i is
the conditional probability that placing an siRNA on the
list creates a type I error, the expected number of false
discoveries, given the data, is
Cð Þ¼
X
i
 iI½ i      7
Therefore, the expected FDR, given the data, is C(k)/J.
Similarly, we can obtain the FDR for selecting inhibi-
tion hits only by replacing  i=1 P(H1|Xi) with
 i=1 P(H2|Xi) and the FDR for selecting both activation
and inhibition hits by replacing  i=1 P(H1|Xi) with
 i=1 P(H1|Xi) P(H2|Xi).
With the control of FDR calculated using the above
method, we may have two major strategies to select hits
in RNAi HTS screens. One is to set up a prespeciﬁc FDR
and search a list of J siRNAs with the smallest posterior
probabilities under the null hypothesis, such that the
expected FDR (namely C(k)/J) given the data equals to
the prespeciﬁc FDR value. The other is to ﬁx the number
(M) of hits to be selected for further analysis, for which we
can rank the siRNAs according to increasing posterior
probabilities under the null hypothesis and select the
ﬁrst M siRNAs as hits. The corresponding FDR is then
the sum of their posterior probabilities under the null
hypothesis divided by M. In addition, if we are interested
in classifying each siRNA as either H0 (no eﬀect), H1
(activation) or H2 (inhibition), this can be achieved by
declaring sample siRNA i to be Hk if ~ pk ¼ max
m
ð~ pmÞ.
Simulations
We conducted two simulation studies to investigate the
performance of our Bayesian approach. The ﬁrst simula-
tion explores the situation where each plate has about the
same number of hits whereas the second simulation
explores the situation in which some of the plates have
an enriched number of hits in each experiment. In both
studies, we simulated data for 100 384-well plates in one
run, each plate having a negative control, an activation
control, an inhibition control, true activation hits, true
inhibition hits and nonhits. Speciﬁcally, in a plate there
were 12 draws from normal distribution N( 0, s
2) for the
negative control, 10 draws from N( 0+4s, s
2) for an
activation control, 10 draws from N( 0 4s, s
2) for an
inhibition control, n1 draws from N( 0+hs, s
2) for acti-
vation hits, n2 draws from N( 0 hs, s
2) for inhibition
hits and 384 32 n1 n2 draws from N( 0,  
2) for nonhits.
 0,   and s were sampled from three continuous uniform
distributions U(4, 5), U(0.5, 0.6) and U(0.35, 0.45), respec-
tively. The three continuous uniform distributions come
from actual RNAi HTS experiments.
For the ﬁrst simulation study, the number of true hits,
n1 and n2, were both drawn from the discrete uniform
distribution U[0, 10] for each run of the 100 plates. For
the second simulation study, in each run, we simulated E
enriched plates and 100-E regular plates where E was a
random draw from 1 to 9. n1 and n2 were both drawn from
the same discrete uniform distribution, U[50, 70], in an
enriched plate and from the discrete uniform distribution,
U[0, 5], in a regular plate. In both studies, the data were
simulated from various scenarios for the strength of true
hits. The strength of a hit is indexed by h, the ratio of the
deviation between the mean of a hit and  0 to the standard
deviation of a control, i.e. h=(mean of a hit  0)/s. Each
scenario was repeated 200 times.
APPLICATIONS AND RESULTS
In the Methods Section, we proposed two Bayesian models
for hit selection in RNAi HTS assays. In Model 1,
we construct the prior using a negative reference, whereas
in Model 2, we construct the prior based on a negative
reference, an activation control and an inhibition control.
Here we apply both Bayesian models to an HIV siRNA
primary screen and a hepatitis C virus (HCV) siRNA
primary screen.
Experiment 1: agenome-scale HIV siRNA screen
A HTS was conducted to identify cellular factors asso-
ciated with HIV replication. In this screen, HeLa P4/R5
cells, which produce  -galactosidase upon infection with
HIV (22), were transfected with siRNAs targeting 18601
genes. Following transfection, the cells were infected with
HXB2 HIV. To allow for the identiﬁcation of host factors
associated with early events, the level of HIV infection
(as determined by  -galactosidase activity) was assessed
at 48h postinfection. The experiment consisted of
96384-well plates. There were 304 sample siRNA wells,
8 negative control wells (Luciferase), 4 moderate inhibi-
tion control wells (CCNT), 16 strong inhibition control
wells (cell no virus) and 4 activation control wells
(TSG-101).
With either model, we have two strategies to select hits
with FDR control: one is to ﬁx the number of selected
siRNAs and the other is to control a prespeciﬁc FDR.
For the ﬁrst strategy, we can obtain the FDR level corre-
sponding to various preset numbers of selected siRNAs.
For the second strategy, we can obtain the number of
selected hits corresponding to various prespeciﬁc FDR
levels. In either strategy, the FDR levels can be obtained
for the selected siRNAs, which eﬀectively addresses the
multiplicity issue of hit selection in RNAi HTS assays.
In contrast, in mean±kSD and median±kMAD, k is
commonly chosen to be 2 or 3, which is based on a
single test. Table 1 displays the results for both models
under various preset number of selected hits or prespeciﬁc
FDR levels.
Based on Table 1, using the ranking strategy in
Model 1, if we select 100 siRNAs as hits, the FDR is
only 0.039; on the other hand, if we select 1000 siRNAs
as hits, the FDR is 0.228. Using the strategy of directly
controlling FDR, if the prespeciﬁed FDR is 0.01, only 31
siRNAs are selected as hits; on the other hand, if the
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One of the goals in a primary screen is usually to select
a set of 500 to 1400 siRNAs with the lowest FDR for
further investigation. With this consideration, it is reason-
able to select hits by controlling the FDR to be somewhere
between 0.25 and 0.35 depending on the capacity available
for conﬁrmation screening or other further investigations.
Model 1 does not use any information about the
strength of the positive controls. Consequently, the hit
selection results using Model 1 are not aﬀected by the
eﬀectiveness of any positive controls in the experiment
(Figure 1A and B). On the other hand, Model 2 does
incorporate the strength of positive controls. Thus, hit
selection results using Model 2 are highly aﬀected by the
positive controls adopted in the experiment. In the HIV
RNAi screen, Model 2 identiﬁes many more inhibition hits
(i.e. 439 inhibition hits) using the moderate inhibition con-
trol compared to those (i.e. 27 inhibition hits) identiﬁed
using the strong inhibition control (Figure 1C and E)
when FDR=0.20. This is because more sample siRNAs
are similar to the moderate control than to the strong
control.
Using our Bayesian models, we get an estimated prob-
ability of each siRNA being in each of the three hypoth-
eses: H0 (no eﬀect), H1 (activation) and H2 (inhibition).
According to the maximal posterior probability among
these hypotheses, we can classify each sample siRNA
into one of the three categories: no eﬀect, activation and
inhibition. In this classifying strategy, we can also obtain
the corresponding FDR by summing up the posterior
probabilities of all selected hits under the null hypothesis
divided by the number of hits. The results are listed in the
bottom rows of Table 1. Using the classifying strategy
based on Model 1, we identiﬁed 816 siRNAs as activation
hits and 536 siRNAs as inhibition hits with a correspond-
ing FDR of 0.312 (Panel A of Table 1 and Figure 1B). As
described earlier, classiﬁcation results based on Model 2
are strongly aﬀected by the strength of the positive con-
trols. For example, there are 2439 siRNAs classiﬁed as
inhibition hits with a FDR of 0.366 if the moderate inhibi-
tion control is used, whereas there are only 41 siRNAs
classiﬁed as inhibition hits with a FDR of 0.282 if the
strong inhibition control is used (Panel B of Table 1 and
Figure 1D and F). This result hints that many siRNAs
have moderate to weak inhibition eﬀects whereas only a
few siRNAs are strongly inhibitory.
When using the commonly used methods such as
mean±kSD and median±kMAD, we also need to
decide whether we should apply the methods experiment-
or plate-wise. In the HIV screen, the between-plate varia-
bility is fairly large. Clearly, the data in plates 1–21 shift
down while the data in plate 79 shift up compared with
the data in the remaining plates. When applying
median±3MAD experiment wise, the inhibition hits are
mostly selected from Plates 1 to 21 and the activation hits
are mostly selected from Plate 79 and plates 22 to 44
(Figure 2C and D). Clearly these results are dominated
by the systematic errors and are unreliable. The plate-
wise hit selection results are more reasonable (Figure 2A
and B). That is one of the major reasons that
median±3MAD is applied plate wise more often than
experiment wise. On the other hand, an experiment-wise
analysis is not aﬀected by the distribution of active
siRNAs between plates whereas a plate-wise analysis
may produce misleading results when a cluster of active
siRNAs is located within a single plate. Our Bayesian
methods allow for sharing of information (experiment-
wise) across plates in a plate-wise analysis and thus,
avoid the need for a decision between plate-wise or
experiment-wise analysis. The distribution of selected
hits across the plates using our Bayesian methods also
looks reasonable (Figure 1A–F).
In the methods of mean±kSD and median±kMAD,
there is a need to decide whether a negative control or the
Table 1. FDR level and number of selected hits in an HIV siRNA screen by Bayesian models
A: Bayesian model 1 B: Bayesian model 2
With moderate inhibition control With strong inhibition control
Fix list size Fix FDR Fix list size Fix FDR Fix list size Fix FDR
Size FDR FDR Size Size FDR FDR Size Size FDR FDR Size
100 0.039 0.01 31 100 0.099 0.01 1 100 0.272 0.01 2
200 0.074 0.05 128 200 0.138 0.05 32 200 0.429 0.05 16
300 0.104 0.10 286 300 0.164 0.10 105 300 0.524 0.10 33
400 0.131 0.15 471 400 0.185 0.15 242 400 0.592 0.15 48
500 0.157 0.20 685 500 0.202 0.20 487 500 0.642 0.20 67
600 0.181 0.25 949 600 0.217 0.25 882 600 0.681 0.30 113
700 0.203 0.30 1266 700 0.230 0.30 1467 700 0.711 0.35 142
800 0.223 0.35 1642 800 0.241 0.35 2254 800 0.736 0.40 176
1000 0.228 0.40 2088 1000 0.262 0.40 3253 1000 0.776 0.50 270
Classify sample siRNAs Classify sample siRNAs Classify sample siRNAs
FDR 0.312 FDR 0.366 FDR 0.282
# activation: 816 # activation: 119 # activation: 64
# inhibition: 536 # inhibition: 2439 # inhibition: 41
# no eﬀect: 26142 # no eﬀect: 24936 # no eﬀect: 27389
Nucleic Acids Research, 2008, Vol. 36, No. 14 4671majority of sample wells should be used as a negative
reference to calculate the mean (or median) and SD
(or MAD). Considering the fact that median±kMAD
is more robust to outliers, we concentrate on the compar-
ison of median±kMAD with our Bayesian methods. For
median±3MAD, if using the negative control as a nega-
tive reference, we will select too many hits either plate wise
(i.e. 8808 hits shown in Figure 2B) or experiment wise
(i.e. 2138 hits shown in Figure 2D). On the other hand,
if using the majority of sample wells as the negative refer-
ence, we will select much fewer hits (i.e. 106 hits shown in
Figure 2A and 29 hits shown in of Figure 2C). Our
Bayesian models do not have such an issue in the deter-
mination of a reference because, from the posteriors
shown in formulas (4) and (5), our Bayesian models natu-
rally combine the information in both the negative control
and sample wells. The numbers of selected hits using
our Bayesian methods are reasonable (e.g. 685 hits with
a FDR of 0.20 shown in Figure 1A and 1352 hits with
a FDR of 0.312 shown in Figure 1B). These methods
control FDR to adjust for multiplicity issues and provide
each siRNA with more than a yes/no answer, but rather
Figure 1. Hits identiﬁed by Bayesian methods with FDR control. In each panel, green, red, light pink, grey, yellow, blue and light blue points
represent a negative control, moderate inhibition control, strong inhibition control, fairly strong activation control, nonhits, activation hits and
inhibition hits, respectively. A and B show the result using priors based on the negative control only; C and D show the results using priors based on
the negative, activation and moderate inhibition controls and E and F show the results using priors based on the negative, activation and strong
inhibition controls.
4672 Nucleic Acids Research, 2008, Vol. 36, No. 14an estimate probability of being in each of three groups:
no eﬀect, activation and inhibition.
Experiment 2: agenome-scale HCV siRNA screen
A primary siRNA HTS experiment was conducted to
identify host factors associated with HCV replication,
using the HCV replicon assay system described in Zuck
et al. (23). Huh-7 cells containing an HCV genotype 1b
replicon with a  -lactamase reporter were transfected with
siRNA pools targeting  19000 genes. Three days after
siRNA transfection, the cells were stained for  -lactamase
expression. siRNAs that decreased  -lactamase expression
were considered to aﬀect HCV replication. The HTS was
conducted using siRNAs in 97 plates, each with 384 wells
(17). In this experiment, there were sample siRNAs
(no replicates in the whole experiment), a strong positive
control that targeted HCV (16 replicates per plate),
a weaker positive control that targeted the HCV host
factor, VAPA (8 replicates per plate) and a negative con-
trol (16 replicates per plate).
The results of hit selection using median±kMAD
experiment wise are dominated by the systematic shift in
the ﬁrst nine plates (Figure 3B). Plate-wise median±
kMAD tends to obtain more reasonable hits in this
screen (Figure 3A). Using Model 1, we not only obtain
more reasonable results (Figure 3C and D) but also
know FDR corresponding to any group of selected hits
(Table 2). Based on Model 1, more inhibition hits were
identiﬁed than activation hits given a prespeciﬁc FDR in
the screen. For example, given a prespeciﬁc FDR of 0.20,
we identiﬁed 290 inhibition hits and 66 activation hits
(Panel A of Table 2 and Figure 3C). Using the classifying
strategy of Model 1, we identify 591 inhibition hits and
150 activation hits, resulting in a FDR of 0.32 (Panel A of
Table 2 and Figure 3D). To obtain a reasonable number
of hits for further investigation while considering the
control of FDR, we may ﬁx the FDR to be somewhere
between 0.25 and 0.40 for hit selection in this screen.
There was no control for identifying siRNAs that
enhanced HCV replication in the screen. Hence, strictly
speaking, the mixture model cannot be applied to this
screen. However, one control appeared to act as an acti-
vation control (gray points in Figure 3). Therefore, we
applied this control as an activation control and apply
Model 2 to identify hits in the inhibition direction only.
The numbers of selected hits corresponding to various
prespeciﬁed FDRs are shown in Panel B of Table 2.
Note, this siRNA was not designed to be an activation
control and is not stable, even resulting in a median
signal less than that of the negative reference in a few
plates (Figure 3). If one uses Model 2 with this control
to identify hits with activation eﬀects, one would obtain
misleading results: some selected activation hits have
values less than the median of the negative control in
some plates (Figure 3E and F). Hit selection using the
classifying strategy of Model 2 is also strongly aﬀected
Figure 2. Hit selection results in the HIV screen, identiﬁed by median±3MAD plate wise (A and B) or experiment wise (C and D) and using the
majority of sample wells (A and C) or a negative control (B and D) as a negative reference. In each panel, green, red, light pink, grey, yellow, blue
and light blue points represent a negative control, moderate inhibition control, strong inhibition control, activation control, nonhits, activation hits
and inhibition hits, respectively.
Nucleic Acids Research, 2008, Vol. 36, No. 14 4673by the quality of positive controls, and can thus generate
similar misleading results (Panel B of Table 2 and
Figure 3F).
ROC analysis of experiments
Receiver operating characteristic curve (ROC) analysis
is commonly used to compare the performance of diﬀer-
ent methods in experiments in which both positive and
negative controls are available and reliable. Here, we
use ROC analysis to compare the performance of our
proposed Bayesian approaches with plate-wise and
experiment-wise median±kMAD methods in both the
HIV and HCV screens. The performance of each method
is assessed via sensitivity (true positive rate) and speciﬁcity
(true negative rate). We used the negative control to
deﬁne the true negative set in either screen. In the HIV
screen, we used all three positive controls (i.e. activation,
moderate inhibition and strong inhibition controls) to
deﬁne the true positive set. In the HCV screen, we used
the two inhibition controls to deﬁne the true positive set.
The ROCs of ﬁve methods (i.e. plate-wise median±
kMAD, experiment-wise median±kMAD, Bayesian
Model 1, Model 2 using the weaker inhibition control
and Model 2 using the stronger inhibition control) in the
HIV and HCV screens are given in Figure 4A and B,
respectively.
As evident in the ROC curves for the HIV screen in
Figure 4A, Bayesian Model 1 has the highest power to
detect the three positive controls given any false positive
Figure 3. Hit selection results in the HCV screen, identiﬁed by median±3MAD plate wise (A) and experiment wise (B) using the majority of sample
wells as a negative reference as well as by Bayesian Model 1 (C and D) and Bayesian Model 2 with the weaker inhibition control (E and F). In a
panel, green, red, light pink, grey, yellow, blue and light blue points represent a negative control, weaker inhibition control, stronger inhibition
control, pseudo activation control, nonhits, activation hits and inhibition hits, respectively.
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Bayesian Model 2 has powers higher than experiment-
wise median±kMAD but lower than plate-wise
median±kMAD and plate-wise median±kMAD per-
forms slightly worse than Bayesian Model 1. As evident
in the ROC curves for the HCV screen in Figure 4B,
Bayesian Model 1 performed better than plate-wise
median±kMAD. Bayesian Model 2 using the weaker
inhibition control performs better than Model 1 when
the false positive rate is in the range of 0 and 0.01 and
worse than Model 1 when the false positive rate is in the
range of 0.01 and 0.05. In both screens, experiment-wise
median±kMAD always has a lower power than plate-
wise median±kMAD given a false positive rate between
0 and 0.1. Bayesian Model 2 with the strong inhibition
control did not perform well in either screen.
Simulation studies
The above results describing the performance of diﬀerent
methods on hit selection in siRNA HTSs are based on
only two experiments. Thus, we conducted simulation
studies as described in the Method Section to investigate
the performance of our Bayesian approach in general.
An exemplary run of simulated data in the ﬁrst simulation
study is shown in Figure 5A1.
We compared the performance of the Bayesian
approach with the commonly used median±kMAD
method via area under the receiver operating characteris-
tic curve (AUROC). For each method, the sensitivity
and speciﬁcity were computed at various target errors a.
k was chosen as  
 1(1 a/2) where   is the cumulative
distribution function of the standard normal distribution.
The sample wells with values greater than median+
kMAD or less than median kMAD were declared to be
hits. For the Bayesian approach, the target error a was the
FDR. The negative control was used to calculate speciﬁ-
city and both activating and inhibiting true hits were
used to calculate sensitivity. ROC curves in one run of
100 plates are shown in Figure 5A2. For each run, the
AUROC was then computed as the area under a ROC
curve. In real RNAi HTS experiments, the value of
the approach is determined by its sensitivity in situations
where the false positive rate is below 0.05 experiment wise,
Table 2. FDR level and number of selected hits using Bayesian models in an HCV siRNA screen
Selection strategy A: Bayesian model 1 prior relying on the negative control B: Bayesian model 2 mixture model
With weaker inhibition control With stronger inhibition control
FDR #INH #ACT FDR #INH #ACT FDR #INH #ACT
Preset FDR 0.01 29 10 0.01 72 10 0.01 9 10
0.05 74 17 0.05 157 17 0.05 13 18
0.10 137 27 0.10 235 22 0.10 15 28
0.15 210 41 0.15 295 41 0.15 16 44
0.20 290 66 0.20 321 106 0.20 18 66
0.25 395 96 0.25 352 195 0.25 19 108
0.30 536 127 0.30 380 334 0.30 19 196
0.35 685 190 0.35 395 579 0.35 19 372
0.40 863 277 0.40 399 1067 0.40 21 801
0.50 1366 574 0.50 528 4349 0.50 23 3968
Classify siRNAs 0.32 591 150 0.38 387 820 0.44 21 1589
Note: ‘#INH’ and ‘#ACT’ indicates the numbers of selected hits with inhibition and activation eﬀects, respectively.
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Therefore, we calculated the AUROC in the situation
where the speciﬁcity is between 0.95 and 1. When the
speciﬁcity is above 0.95, a null method that randomly
declares hits has a value of 0.00125 for AUROC and a
perfect method has a value of 0.05 for AUROC.
Figure 5B1–5 show the AUROC results in the ﬁrst study
and C1–5 show the AUROC results in the second study
(Figure 5). Each panel summarizes the AUROC for 200
runs from diﬀerent strengths of true hits.
From B1–5 of Figure 5 for the ﬁrst study, Bayesian
Model 1 overall has the largest AUROC in all sce-
narios, especially when the true hits have weak to moderate
eﬀects. Employing plate-wise median±kMAD tends to
result in an AUROC slightly less than Bayesian Model 1.
Using experiment-wise median±kMAD resulted in the
smallest AUROC of all three scenarios tested. Bayesian
Model 2 resulted in an AUROC between Bayesian
Model 1 and experiment-wise median±kMAD. There-
fore, the ﬁrst simulation study suggests that, in
an experiment without any enriched plates, Bayesian
Model 1 is the most eﬀective method, especially with
regard to detecting hits with weak or moderate eﬀects;
followed by the use of the plate-wise median±kMAD
method, Bayesian Model 2 and ﬁnally by the use of the
experiment-wise median±kMAD method.
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Figure 5. Simulated data and results. A1 shows a simple realization of 100 plates in 1 run of the ﬁrst simulation with h=1 where
h ¼ð mean of a hit  0Þ= . In this panel, green, red, gray and yellow points represent a negative control, inhibition control, activation control
and nonhits, respectively; blue and light blue crosses represent activation and inhibition hits, respectively. A2 shows the ROC curves by applying
four methods to the data in A1. B1 B5 (and C1 C5) show AUROC’s for the speciﬁcity between 1 and 0.95 in the ﬁrst (and second) simulation
study with h=1, 2, 3, 4 and 5, respectively. In each A1, B1–B5 and C1–C5, the Bayesian models 1–2, plate-wise and experiment-wise
median±kMAD are labeled as BayesM1 (red), BayesM2 (green), PLT wise (blue) and EXP wise (light blue), respectively.
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We proposed a methodology for hit selection in genome-
scale RNAi HTS based on a Bayesian framework. The
proposed methodology aims to address issues arising
from classical approaches including median±kMAD.
One issue is the adjustment of error rate in multiple
hypothesis testing. In this article, we construct Bayesian
models to control FDR via the direct posterior probability
approach (19). The second issue is the decision of whether
a plate-wise or experiment-wise analysis should be used.
The results in both HIV and HCV siRNA screens show
that selected hits using an experiment-wise analysis can be
dominated by systematic errors in a plate. A plate-wise
analysis is more robust in the presence of systematic
errors, but can result in false negatives in plates containing
a cluster of true hits. Our proposed Bayesian methodology
allows data to be shared across the plates of an experiment
in a plate-wise analysis, thus obviating the need for choos-
ing either plate-wise or experiment-wise analysis. The
third issue is the use of controls: Should the negative con-
trol or the majority of sample wells be used as the negative
reference when calculating the center and variability of the
raw data? How should the information from positive and
negative controls with varying degrees of eﬃcacy be incor-
porated into the hit selection strategy? The choice of prior
in our Bayesian methods enables us to incorporate infor-
mation from various controls. From the posteriors in the
proposed models, our Bayesian approach maintains a
balance between the contribution from the sample wells
and control wells. In addition, outliers are identiﬁed and
excluded in the estimation of parameters in our Bayesian
methods; thus our methods are robust to outliers. Finally,
the Bayesian approach provides each siRNA with more
than a yes/no answer, but rather an estimate probability
of being in each of three groups: activation, inhibition and
no eﬀect.
We applied the Bayesian methods to two real genome-
scale RNAi screens with diﬀerent features. The HCV
screen did not have a true activation control whereas the
HIV screen did. The inhibition controls had data vari-
ability larger than the negative control in the HIV screen
whereas the inhibition controls had data variability
smaller than the negative control in the HCV screen.
The strength of positive controls in the two screens also
diﬀered from each other. By using the Bayesian methods
for hit selection we describe here, we were able to address
eﬀectively the issues of hit selection common to both
screens and to obtain a reasonable pool of selected hits
for both screens despite the diﬀerences between the two.
We focus on two Bayesian models for hit selection in
RNAi HTS assays. In Model 1, we construct the prior
using a negative reference, whereas in Model 2, we con-
struct the prior based on a negative reference, an activa-
tion control and an inhibition controls. We apply both
Bayesian models for hit selection in an HIV siRNA pri-
mary screen and an HCV siRNA primary screen. The
applications show that the hit selection results using our
proposed methods, especially Model 1, are more reason-
able than those using classical methods (Figures 2–4).
ROC analysis in the case studies shows that Model 1 is
more powerful than the commonly used classical
approaches. When the positive controls are moderately
eﬀective and of high quality, Model 2 is also powerful
(Figure 4B). Simulation studies show that, in an experi-
ment without any enriched plates, in general, Bayesian
Model 1 has the best performance especially in detecting
hits with weak or moderate eﬀects; while Bayesian
Model 2 performs better than the experiment-wise
median±kMAD method and has a good performance
in detecting hits with eﬀects equal to or stronger than
the positive controls (Figure 5B1–5). In an experiment
with 1 to 9 enriched plates, in general, Bayesian Model 1
has the best performance in detecting hits with weak or
moderate eﬀects, while Bayesian Model 2 performs
equivalently to classical experiment-wise methods in
detecting hits with strong eﬀects (Figure 5C1–5).
Bayesian Models 1 and 2 allow for three strategies
to select hits: (i) ﬁx the number of selected siRNAs,
(ii) control a prespeciﬁc FDR or (iii) classify an siRNA
based on its maximal posterior probability. In a typical
primary siRNA HTS screen, one of the goals is usually to
select a practical number (usually some number between
500 and 1500) of hits for further investigation. Therefore,
there is a motivation to use the ﬁrst strategy for hit selec-
tion in a primary screen. Our Bayesian methods allow
selecting a ﬁxed number of siRNAs with the lowest
FDR. On the other hand, we cannot simply select a
ﬁxed number (say 1000) from every screen and ignore
the error rate because diﬀerent screens may have very
diﬀerent error rates. Thus, the second strategy may be
more plausible especially when we want to control some
ﬁxed error rate in most screens. Considering both HIV
and HCV screens discussed in this article, a reasonable
choice of a ﬁxed FDR is somewhere between 0.25 and
0.35, which allows us not only to ﬁx a reasonable
number of siRNAs for further analysis but also to control
the FDR within reasonable range. The classifying strategy
under Model 1 also works eﬀectively in the two screens,
which yields an FDR of around 0.30 and a reasonable
number of selected hits (i.e. 1352 hits in the HIV screen
and 741 hits in the HCV screen).
Model 1 does not use any information about the
strength of positive controls. Consequently, the hit selec-
tion results using Model 1 are robust to the quality and
strength of any positive controls used in the experiment.
On the other hand, Model 2 incorporates the strength
of positive controls. Thus, hit selection results using
Model 2 are highly sensitive to the data quality and
strength of positive controls adopted in the experiment.
It is not uncommon that the strength of positive controls
varies within or between experiments. It is also not
uncommon that the data quality of positive controls is
poor in some experiments. These facts make Model 1
more favorable than Model 2 for hit selection in RNAi
HTS screens. On the other hand, the simulation studies
show that Model 2 has a better performance in detecting
hits with eﬀects equal to or stronger than the positive
controls when there are plates with enriched number
of hits (Figure 5C1–5). If the data quality of positive
controls is good and the positive controls are moder-
ately or fairly strongly eﬀective, Model 2 may be more
Nucleic Acids Research, 2008, Vol. 36, No. 14 4677powerful (Figure 4B). Thus, Model 2 may help us to
identify siRNAs with a desired potency if there are high
quality and reliable controls with a similar eﬀectiveness in
the screen.
In our Bayesian methods, we preestimate some para-
meters in the priors, resulting in a fast and eﬃcient
algorithm. There are two reasons for the preestimation.
One is to reduce computational time because it is critical
to keep computational time as low as possible when ana-
lyzing large data sets from high-throughput screens. The
second reason is to focus on selecting hits only in plates
with good data quality, because hit selection results are
often misleading in plates with poor quality (24–29). In the
Bayesian models described in this article, we use the fact
that the unconditional variance of an observed value
should be larger than the expectation of its conditional
variance (i.e. VarðXiÞ > E½VarðXij iÞ  ¼  2) in a plate
with good quality. In a plate with poor data quality, the
pooled variance from diﬀerent controls (i.e. estimate
of s
2) could be greater than the variability of sample
wells (i.e. estimate of Var (Xi)) in a plate. In such a case,
the estimate of  
2 is zero (i.e. ^  2 ¼ 0); consequently, the
FDR is unavailable in that plate when using the above
Bayesian models.
One strategy to handle the situation with ^  2 ¼ 0 is the
use of quality control methods described in (24–29) to
assure all the plates have good quality during the experi-
mental stage of a screen, thus preventing the occurrence
of ^  2 ¼ 0. Another strategy is to select hits in the plates
with ^  2 ¼ 0 using non-Bayesian methods such as those
described in (5–7,10,13,17) and then to put a warning on
all the hits from these plates. The third strategy is to build
a Bayesian hierarchical model that puts priors on  
2
and/or other preestimated parameters. For example, we
may construct a hierarchical model as follows:  ð Þ/ =
ð 2 þ  2Þ,  ij    N  0, 2   
and Xij i   N  i, 2   
where  0
and s
2 are preestimated as in Model 1. This leads to the
posteriors:
 2 þ  2jXi   Inverse Gamma
1
2
,
ðXi    0Þ
2
2
  
and
 ij ,Xi   N
Xi 2 þ  0 2
 2 þ  2 ,
 2 2
 2 þ  2
  
:
Based on these posteriors, we make inference on  i using
direct sampling in the Monte Carlo simulation.
There are two major issues with hierarchical models:
one is the long computational time and the other is that
plates with good or poor quality are treated in the same
way. For example, for the simple hierarchical model
described above, we need to run direct sampling on each
of 25000 siRNAs tested. The number of iterations in the
Monte Carlo simulation for each siRNA has to be large.
Otherwise, due to sampling error, we may obtain incorrect
results: i.e. a more eﬀective siRNA may have less chance
to be selected as a hit than a less eﬀective siRNA in the
same plate. Even if only 2000 iterations are used for each
siRNA, this will result in a total of 50000000 iterations
when analyzing data from an HTS screen. Building more
layers in a hierarchical model will result in even longer
computational time, especially when there is at least one
posterior requiring an indirect sampling in the Monte
Carlo simulation (30). Therefore, in genome-wide RNAi
primary screens, we do not recommend the use of
Bayesian hierarchical models (especially those requiring
the use of indirect sampling) although we may use them
in conﬁrmatory screens.
In summary, hit selection in genome-scale RNAi
research is important for identifying targets for a new
class of therapeutics for treating human diseases. The
development of novel eﬀective and powerful analytic
methods for hit selection is critical to glean useful infor-
mation from mounds of data. In this article, we propose a
methodology based on a Bayesian framework. The case
studies show that our methods eﬀectively address multiple
issues in classical methods including error rate issues in
multiple hypothesis testing, experiment-wise versus plate-
wise analysis and incorporation of information from
multiple reliable controls. Both simulation and case stu-
dies show that the Bayesian Model 1 we describe is more
powerful than classical methods in detecting siRNAs with
weak and moderate eﬀects. Our Bayesian Model 2 per-
forms better than classical experiment-wise methods
when there are no plates with enriched number of hits
and performs equivalently to experiment-wise classical
methods in detecting hits with strong eﬀects when there
are plates with enriched number of hits in an RNAi HTS
experiment.
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